FDA gives Roche immunotherapy drug priority review

Dec 05, 2018

The FDA has awarded Roche an accelerated review of its immunotherapy drug, Tecentriq, to treat non small-cell lung cancer. 

Tecentriq was given priority review as a treatment mixed with chemotherapy. In September, Roche announced results from a study showing that patients receiving Tecentriq in combination with chemotherapy lived a median of 12.3 months, compared to 10.3 months with chemo alone. 

In the market for immuno-oncology drugs, Roche has been lagging behind competition from Mercky’s Keytruda and Bristol Myers Squibb’s Opdivo, which have already been approved for several indications. But with the latest FDA nod, Roche said that Tecentriq could be approved for the lucrative market for non small-cell lung cancer by March 18. 

Tecentriq is already being used to treat later-stage lung and bladder cancers. 

Read the full Reuters report.

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments